---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Administration"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Administration. Topics: Administration: single MRI-guided convection-enhanced stereotactic delivery into the caudate and putamen, Number of infusions per hemisphere, Burr holes and micro-catheter placement under general anesthesia, Procedure duration stated in the eligibility criteria of the European study, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/administration"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Administration

<a id="heading-2.1.2.10.2"></a>

## 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

### Administration: single MRI-guided convection-enhanced stereotactic delivery into the caudate and putamen

> “Treated patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

> “One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-2.1.2.10.2-2"></a>

### Number of infusions per hemisphere

> “3 infusions per hemisphere”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-2.1.2.10.2-3"></a>

### Burr holes and micro-catheter placement under general anesthesia

> “This is done by drilling two to six small holes in the skull and administering AMT-130 by a micro-catheter.”
> “AMT-130 is delivered directly to the brain and will include risks associated with general anesthesia and micro-catheter placement in the brain.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.10.2-4"></a>

### Procedure duration stated in the eligibility criteria of the European study

> “Current or recurrent disease (including pre-existing cardiovascular or pulmonary conditions), infection, or other significant concurrent medical condition or medications that could confound clinical and laboratory evaluations or could affect a participant's safety or their ability to undergo a neurosurgical procedure (10+ hour surgical procedure) or comply with the procedures and study visit schedule.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.10.2-5"></a>

### Delivery method described in a review of neurosurgical therapies for Huntington's disease

> “In clinical trials, a current Phase 1/2 study funded by UniQure Biopharma includes patients with early manifestations of HD (ages 25–65 years) and uses bilateral striatal injection of AAV5-mHTT using an MRI-guided convection-enhanced delivery method and sham surgery for the randomized control arm”
> “Although technically possible, manual infusion does not offer the control and consistency of more advanced techniques”
> “namely MRI-guided convection-based delivery using a pressure gradient generated by a pump.”
> “Stereotactic neurosurgical techniques will be critical in optimizing therapeutic efficacy through safe, reproducible treatment delivery.”

Source: [Kim et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11585891/)

<a id="topic-2.1.2.10.2-6"></a>

### Convection-enhanced delivery: method and the role of real-time imaging

> “CED, on the other hand, uses a pressure gradient generated by an automated pump to distribute high concentrations of macromolecules over significant volumes within the brain parenchyma by fluid convection, allowing for measurable, consistent and predictable infusion rates.”
> “One major challenge has been the lack of real-time visualisation of vector delivery, without which it is difficult to improve the distribution of vector during infusions.”
> “This new paradigm allows visualisation of the accuracy and adequacy of viral vector delivery within target structures, enabling intertrial modifications in surgical approaches, cannula design, vector volumes and dosing.”

Source: [Richardson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7569395/)

<a id="topic-2.1.2.10.2-7"></a>

### Cannula design and backflow during intraparenchymal infusion

> “Features of the design of the infusion cannula for CED can profoundly impact successful delivery of gene therapy.”
> “Combined with increased infusion flow rates, these modifications resulted in greatly improved target coverage when evaluated in NHPs.”

Source: [Richardson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7569395/)

<a id="topic-2.1.2.10.2-8"></a>

### Administration of the approved intraputaminal gene therapy eladocagene exuparvovec: setting and infusion parameters

> “KEBILIDI should be administered in a medical center which specializes in stereotactic”
> “KEBILIDI is administered as four intraputaminal infusions in a single stereotactic neurosurgical”
> “Administer KEBILIDI only using an FDA-authorized cannula for intraparenchymal”
> “KEBILIDI is intended to be administered with an infusion pump capable of infusing at a”

Source: [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download)

| Field | Quoted record |
| --- | --- |
| Total recommended dose | “1.8x1011 vg (0.32 mL)” |
| Volume (dose) per infusion | “0.08 mL (0.45x1011 vg)” |
| Location of infusions | “2 in anterior putamen, 2 in posterior putamen” |
| Infusion rate at each target point | “0.003 mL/min” |
| Dose duration for infusion at each target point | “27 minutes” |

Source: [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
